Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8830081 | 0.74 | GPR3 (0.37) | GPR3PKM | |
| SCHEMBL276368 | 0.74 | GPR3 (0.37) | GPR3PKM | |
| SCHEMBL30659172 | 0.74 | GPR3 (0.37) | GPR3PKM | |
| SCHEMBL276369 | 0.74 | KDM4E (0.44) | GPR3PKM | |
| SCHEMBL3884735 | 0.74 | CYP1A2 (0.44) | GPR3PKM | |
| SCHEMBL25095968 | 0.74 | CYP1A2 (0.44) | GPR3PKM | |
| SCHEMBL2008423 | 0.74 | ALDH1A1 (0.50) | GPR3PKM | |
| SCHEMBL2008421 | 0.74 | GPR3 (0.37) | GPR3PKM | |
| SCHEMBL19001493 | 0.74 | GPR3 (0.37) | GPR3PKM | |
| SCHEMBL20019413 | 0.74 | GPR3 (0.37) | GPR3PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10000476-B2 | Pyridone derivative, pharmaceutical containing the same and methods of use thereof | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2018-06-19 | — | — | US | disclosed |
| EP-2789607-B1 | PYRIDONE DERIVATIVE AND MEDICINE CONTAINING SAME | KAKEN PHARMA CO LTD (JP) | 2018-02-07 | — | — | EP | disclosed |
| CN-105392482-B | Composition for maintaining hematoblastic function | 科研制药株式会社 | 2017-08-08 | — | — | CN | disclosed |
| US-20160340349-A1 | PYRIDONE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2016-11-24 | — | — | US | disclosed |
| US-9447072-B2 | Pyridone derivative and pharmaceutical containing same | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2016-09-20 | — | — | US | disclosed |
| CN-103987706-B | Pyridione derivatives and the medicine containing Pyridione derivatives | 科研制药株式会社 | 2016-06-29 | — | — | CN | disclosed |
| US-20160168540-A1 | COMPOSITION FOR MAINTAINING PLATELET FUNCTION | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2016-06-16 | — | — | US | disclosed |
| EP-3006029-A1 | COMPOSITION FOR MAINTAINING PLATELET FUNCTION | Kaken Pharmaceutical Co., Ltd. (JP) | 2016-04-13 | — | — | EP | disclosed |
| CN-105392482-A | Composition for maintaining platelet function | KAKEN PHARMA CO LTD | 2016-03-09 | — | — | CN | disclosed |
| US-20150166506-A1 | PYRIDONE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2015-06-18 | — | — | US | disclosed |
| EP-2789607-A1 | PYRIDONE DERIVATIVE AND MEDICINE CONTAINING SAME | Kaken Pharmaceutical Co., Ltd. (JP) | 2014-10-15 | — | — | EP | disclosed |
| CN-103987706-A | Pyridone derivative and medicine containing same | KAKEN PHARMA CO LTD | 2014-08-13 | — | — | CN | disclosed |
| US-7511144-B2 | Reverse hydroxamic acid derivatives | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2009-03-31 | — | — | US | disclosed |
| EP-1431285-B1 | REVERSE HYDROXAMIC ACID DERIVATIVES | KAKEN PHARMA CO LTD (JP) | 2009-01-07 | — | — | EP | disclosed |
| US-20040242928-A1 | Tumor necrosis factor converting enzyme inhibitor; antiarthritic agents; lupus; Crohn's disease; multiple sclerosis; antidiabetic agents; infections;; asthma; skin disorders; anemia | STUDOR S.A. (LU) | 2004-12-02 | — | — | US | disclosed |
| EP-1431285-A1 | REVERSE HYDROXAMIC ACID DERIVATIVES | Kaken Pharmaceutical Co., Ltd. (JP) | 2004-06-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160340349-A1 | PYRIDONE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME | PLPBP, PDXK, PNPO | GPR3 2428/4885PKM 178/4885 |
| US-10000476-B2 | Pyridone derivative, pharmaceutical containing the same and methods of use thereof | PNPO, PDXK, PLPBP | GPR3 2354/4885PKM 198/4885 |
| US-20160168540-A1 | COMPOSITION FOR MAINTAINING PLATELET FUNCTION | PF4, F2, PFKP | GPR3 1936/4885PKM 606/4885 |
| US-20150166506-A1 | PYRIDONE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME | PLPBP, PDXK, PNPO | GPR3 2428/4885PKM 178/4885 |
| US-20040242928-A1 | Tumor necrosis factor converting enzyme inhibitor; antiarthritic agents; lupus; Crohn's disease; multiple sclerosis; antidiabetic agents; infections;; asthma; skin disorders; anemia | TNF, RNASE1, IFNAR1 | GPR3 2450/4885PKM 3917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.